{"title":"A novel VPS4A variant drives lipotoxicity underlying CIMDAG syndrome","authors":"Apurva Gupta MD, Yogendra Pratap Mathuria MD, Buddhi Prakash Jain PhD, Shailesh Kumar Gupta PhD, Debasish Kumar Ghosh PhD","doi":"10.1016/j.jacl.2026.07.007","DOIUrl":null,"url":null,"abstract":"<div><div>Cerebellar hypoplasia, impaired intellectual development, congenital microcephaly, dystonia, anemia, and growth retardation (CIMDAG) syndrome is caused by variants in <em>VPS4A</em>. We report a 5-year-old Nepalese boy with classical CIMDAG features, including developmental delay, microcephaly, dystonia, cataracts, dyserythropoietic anemia, and growth retardation. Magnetic resonance imaging showed mild cerebellar atrophy. Trio exome sequencing identified a homozygous <em>VPS4A</em> variant (c.863G>A; p.Arg288Gln), predicted to be deleterious. Structural analyses revealed disruption of a conserved Arginine-288 residue within the ATPases associated with diverse cellular activities domain, leading to loss of stability and increased disorder. The <em>VPS4A</em>-p.Arg288Gln variant showed enhanced aggregation and reduced interaction with LC3B (microtubule-associated protein 1 light chain 3 beta), impairing its localization to lipid droplets. Proband fibroblasts exhibited increased lipid accumulation, elevated free fatty acids, and higher reactive oxygen species levels, indicative of lipotoxic stress. Together, these findings demonstrate that a novel pathogenic <em>VPS4A</em> variant drives structural destabilization and lipotoxicity, providing mechanistic insight into lipid homeostasis perturbations in CIMDAG syndrome.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 2069-2077"},"PeriodicalIF":6.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287426004368","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Cerebellar hypoplasia, impaired intellectual development, congenital microcephaly, dystonia, anemia, and growth retardation (CIMDAG) syndrome is caused by variants in VPS4A. We report a 5-year-old Nepalese boy with classical CIMDAG features, including developmental delay, microcephaly, dystonia, cataracts, dyserythropoietic anemia, and growth retardation. Magnetic resonance imaging showed mild cerebellar atrophy. Trio exome sequencing identified a homozygous VPS4A variant (c.863G>A; p.Arg288Gln), predicted to be deleterious. Structural analyses revealed disruption of a conserved Arginine-288 residue within the ATPases associated with diverse cellular activities domain, leading to loss of stability and increased disorder. The VPS4A-p.Arg288Gln variant showed enhanced aggregation and reduced interaction with LC3B (microtubule-associated protein 1 light chain 3 beta), impairing its localization to lipid droplets. Proband fibroblasts exhibited increased lipid accumulation, elevated free fatty acids, and higher reactive oxygen species levels, indicative of lipotoxic stress. Together, these findings demonstrate that a novel pathogenic VPS4A variant drives structural destabilization and lipotoxicity, providing mechanistic insight into lipid homeostasis perturbations in CIMDAG syndrome.
期刊介绍:
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner.
Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.